Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice

Molecular Pharmacology

Volumn 85, Issue 5, 2014, Pages 715-722

  Oda, Masayuki ^a   Koyanagi, Satoru ^a   Tsurudome, Yuuya ^a   Kanemitsu, Takumi ^a   Matsunaga, Naoya ^a   Ohdo, Shigehiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; MESSENGER RNA; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC CATION TRANSPORTER 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; KIDNEY CLEARANCE; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; CIRCADIAN CLOCKS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; NIH 3T3 CELLS; ORGANIC CATION TRANSPORT PROTEINS; TIME FACTORS;

EID: 84897446729     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089805     Document Type: Article

References (47)

1. Asher G and Schibler U (2011) Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metab 13:125-137.
2. Bass J and Takahashi JS (2010) Circadian integration of metabolism and energetics. Science 330:1349-1354.
3. Bélanger PM, Bruguerolle B, and Labrecque G (1997) Rhythms in pharmacokinetics: absorption, distribution, metabolism, and excretion. Handbook Exp Pharmacol 125:177-204.
4. Boughattas NA, Lévi F, Fournier C, Hecquet B, Lemaigre G, Roulon A, Mathé G, and Reinberg A (1990) Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharmacol Exp Ther 255:672-679.
5. Cheng MY, Bullock CM, Li C, Lee AG, Bermak JC, Belluzzi J, Weaver DR, Leslie FM, and Zhou QY (2002) Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 417:405-410.
6. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, and Duverger N et al. (2001) PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58.
7. dos Santos NA, Carvalho Rodrigues MA, Martins NM, and dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86:1233-1250.
8. Farris FF, Dedrick RL, and King FG (1988) Cisplatin pharmacokinetics: applications of a physiological model. Toxicol Lett 43:117-137.
9. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, and Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396-402.
10. Gachon F, Fonjallaz P, Damiola F, Gos P, Kodama T, Zakany J, Duboule D, Petit B, Tafti M, and Schibler U (2004) The loss of circadian PAR bZip transcription factors results in epilepsy. Genes Dev 18:1397-1412.
11. Gachon F, Olela FF, Schaad O, Descombes P, and Schibler U (2006) The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 4:25-36.
12. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, Takahashi JS, and Weitz CJ (1998) Role of the CLOCK protein in the mammalian circadian mechanism. Science 280:1564-1569.
13. Göttlicher M, Widmark E, Li Q, and Gustafsson JA (1992) Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653-4657.
14. Green CB, Takahashi JS, and Bass J (2008) The meter of metabolism. Cell 134:728-742.
15. Hrushesky WJ, Levi FA, Halberg F, and Kennedy BJ (1982) Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res 42: 945-949.
16. Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ, and Reppert SM (1999) A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 96:57-68.
17. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, and Koepsell H (2000) Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 279: F679-F687.
18. Katada S and Sassone-Corsi P (2010) The histone methyltransferaseMLL1 permits the oscillation of circadian gene expression. Nat Struct Mol Biol 17:1414-1421.
19. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, and Wahli W (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90:2160-2164.
20. Koyanagi S, Hamdan AM, Horiguchi M, Kusunose N, Okamoto A, Matsunaga N, and Ohdo S (2011) cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the Period2 gene. J Biol Chem 286:32416-32423.
21. Labrecque G and Bélanger PM (1991) Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 52:95-107.
22. Lange RC, Spencer RP, and Harder HC (1972) Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum. II. J Nucl Med 13:328-330.
23. Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathé G (1990) Chemotherapy of advanced ovarian cancer with 49-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 8: 705-714.
24. Levi FA, Hrushesky WJ, Halberg F, Langevin TR, Haus E, and Kennedy BJ (1982a) Lethal nephrotoxicity and hematologic toxicity of cis- diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol 18:471-477.
25. Levi FA, Hrushesky WJ, Blomquist CH, Lakatua DJ, Haus E, Halberg F, and Kennedy BJ (1982b) Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 42:950-955.
26. Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, and Portilla D (2004) PPAR a ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 286: F572-F580.
27. Li S, Gokden N, Okusa MD, Bhatt R, and Portilla D (2005) Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 289: F469-F480.
28. Litterst CL (1981) Alterations in the toxicity of cis- dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61:99-108.
29. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, and Lee ME (2000) CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression.J BiolChem275:36847-36851.
30. Martin G, Schoonjans K, Lefebvre AM, Staels B, and Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 272: 28210-28217.
31. Miller RP, Tadagavadi RK, Ramesh G, and Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2:2490-2518.
32. Montero TD, Racordon D, Bravo L, Owen GI, Bronfman ML, and Leisewitz AV (2012) PPARa and PPARg regulate the nucleoside transporter hENT1. Biochem Biophys Res Commun 419:405-411.
33. Morf J, Rey G, Schneider K, Stratmann M, Fujita J, Naef F, and Schibler U (2012) Cold-inducible RNA-binding protein modulates circadian gene expression posttranscriptionally. Science 338:379-383.
34. Nagothu KK, Bhatt R, Kaushal GP, and Portilla D (2005) Fibrate prevents cisplatininduced proximal tubule cell death. Kidney Int 68:2680-2693.
35. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, and Inui K (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80:1762-1767.
36. Ohdo S (2007) Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet 22:3-14.
37. Ohdo S (2010) Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev 62:859-875.
38. Oishi K, Shirai H, and Ishida N (2005) CLOCK is involved in the circadian transactivation of peroxisome-proliferator-activated receptor a (PPARalpha) in mice. Biochem J 386:575-581.
39. Oishi K, Uchida D, and Ishida N (2008) Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver. FEBS Lett 582:3639-3642.
40. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102:17923-17928.
41. Pabla N and Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007.
42. Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, and Schibler U (2002) The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110:251-260.
43. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, and Breyer MD (2004) Serial determination of glomerular filtration rate in conscious mice using FITCinulin clearance. Am J Physiol Renal Physiol 286:F590-F596.
44. Siddik ZH, Newell DR, Boxall FE, and Harrap KR (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36: 1925-1932.
45. Terada T and Inui KI (2007) Gene expression and regulation of drug transporters in the intestine and kidney. Biochem Pharmacol 73:440-449.
46. Urakami Y, Okuda M, Masuda S, Saito H, and Inui KI (1998) Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 287:800-805.
47. Yonezawa A, Masuda S, Yokoo S, Katsura T, and Inui K (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organicfication transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879-886.